Evolus (EOLS) vs Glass House Brands Subordinate Voting Shares (GLAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Glass House Brands Subordinate Voting Shares (GLAS) over the past year, gaining 23.6% versus a loss of 36.7%. Over five years, GLAS leads with a +2.7% price change compared with +0.9% for EOLS. Evolus is the larger company by market cap ($511.2 million vs $483.5 million), about 1.1 times the size.
On valuation, Glass House Brands Subordinate Voting Shares trades at a lower forward P/E (22.8x vs 26.5x for Evolus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | GLAS |
|---|---|---|
| Share price | $7.74 | $5.13 |
| Market cap | $511.23M | $483.46M |
| 1-day change | +4.88% | -0.58% |
| YTD return | +16.39% | -42.03% |
| 1-year return | +23.64% | -36.67% |
| 5-year return | +0.91% | +2.70% |
| Forward P/E | 26.46 | 22.80 |
| EPS (TTM) | $-0.53 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $13.93 |
| 52-week low | $3.86 | $4.97 |
| Distance from 52-week high | -16.86% | -63.17% |
| Analyst consensus | none | none |
| Avg. price target upside | +93.80% | +211.89% |
| Average volume | 901.46K | 735.63K |
| Shares outstanding | 66.05M | 88.00M |
| Employees | 353 | 357 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed GLAS by 60.3 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Glass House Brands Subordinate Voting Shares
GLAS stock →Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. It operates through three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods.
Health Care · Medicinal Chemicals and Botanical Products · 357 employees
EOLS vs GLAS FAQ
Which is bigger, Evolus or Glass House Brands Subordinate Voting Shares?
Evolus (EOLS) is larger, with a market capitalization of $511.23M compared with $483.46M for Glass House Brands Subordinate Voting Shares (GLAS).
Which stock has performed better over the past year, EOLS or GLAS?
EOLS returned +23.64% over the past 12 months, compared with -36.67% for GLAS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Glass House Brands Subordinate Voting Shares in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Evolus and Medicinal Chemicals and Botanical Products for Glass House Brands Subordinate Voting Shares.